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Abstract: Prion diseases or transmissible spongiform encephalopathies are a unique 
category of infectious protein-misfolding neurodegenerative disorders. Hypothesized to be 
caused by misfolding of the cellular prion protein these disorders possess an infectious 
quality that thrives in immune-competent hosts. While much has been discovered about the 
routing and critical components involved in the peripheral pathogenesis of these agents 
there are still many aspects to be discovered. Research into this area has been extensive as 
it represents a major target for therapeutic intervention within this group of diseases. The 
main focus of pathological damage in these diseases occurs within the central nervous 
system. Cells of the innate immune system have been proven to be critical players in the 
initial pathogenesis of prion disease, and may have a role in the pathological progression of 
disease. Understanding how prions interact with the host innate immune system may 
provide us with natural pathways and mechanisms to combat these diseases prior to their 
neuroinvasive stage. We present here a review of the current knowledge regarding the role 
of the innate immune system in prion pathogenesis. 
Keywords: prion disease pathogenesis; transmissible spongiform encephalopathy; innate 
immune system 
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1. Introduction 
1.1. Prion Diseases 
Prion diseases or transmissible spongiform encephalopathies (TSEs) are infectious neurodegenerative 
conditions characterized by vacuolar degeneration of the central nervous system (CNS) and deposition 
of an abnormal isoform of the host-encoded prion protein (PrP). These diseases affect a wide variety of 
animal species and display limited zoonotic potential. Usually displaying prolonged incubation 
periods, they are clinically recognized via progressive neurological deterioration resulting from 
synaptic and neuronal loss and associated activated glial responses to CNS damage. Identification of 
genetically inherited forms of these diseases implicate further the critical role of the prion protein in 
disease pathogenesis and their classification as protein-misfolding disorders, with similarities to other 
progressive dementias such as Alzheimer’s and Parkinson’s diseases and amyotrophic lateral sclerosis. 
Sporadic prion diseases, with no known genetic risk factor or exposure to infection, have also been 
identified. The disease-associated isoform of the prion protein gains several properties including ability 
to transmit infection, limited protease resistance, and increased ability to fibrillize and form amyloid, 
these observations on both etiology and biochemical nature of the agent resulted in the prion 
hypothesis [1].  
The prion hypothesis proposed that the infectious agent may be solely composed of a proteinaceous 
particle, i.e., the disease-associated isoform of the prion protein (PrPSc), with the means to  
self-propagate via an auto-catalytic process of template-mediated refolding of the nascent cellular 
prion protein (PrPC). The pathway and mechanisms from refolding of the prion protein to 
neurodegeneration are still unknown. The peripheral pathogenesis of these diseases have been 
extensively studied using animal models, as mice are naturally susceptible to both sheep scrapie and 
bovine spongiform encephalopathy (BSE). Following natural peripheral exposure to prion agents, 
infection is usually sequestered to lymphoid organs prior to invasion of the nervous system (termed 
neuroinvasion) [2,3]. In the absence of local draining lymphoid tissue, subsequent circulation to other 
lymphoid organs and neuroinvasion are ultimately blocked [4,5]. Using transgenic mouse models or 
bone marrow chimeric mouse models various hypotheses regarding the genes and cells involved in the 
prion infectious pathway have been proven or refuted. Though often contradictory, results from these 
studies have revealed that disease-associated PrP is deposited in lymphoid follicles and replicates upon 
follicular dendritic cells (FDCs). This stage of pathogenesis has been shown to be dependent upon 
expression of cellular prion protein by FDCs [6,7]. The lymphoid stage of prion pathogenesis is not 
always obligatory and is dependent upon various factors including: the host, strain of infectious agent, 
route of infection and infectious dose [8–11]. Experimental delivery of prion agent directly to the 
nervous system may facilitate direct neuroinvasion [12,13]. Direct delivery of the prion agent to the 
central nervous system may bypass peripheral pathogenesis completely resulting in infection in 
naturally resistant hosts [14,15]. Concurrent lymphoid sequestration of infection likely still occurs after 
direct CNS infection and may play a role in subsequent pathogenesis [15,16]. 
Originating from the stromal cell compartment FDC are specialized cells that capture and retain 
antigen for presentation to cognate B-cells and subsequent generation of specific antibody responses 
and thus reside within primary B-cell follicles and germinal centers within lymphoid tissues [17,18]. 
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Due to the reliance of FDCs on lymphotoxin signaling from B-cells to maintain FDC homeostasis [19], 
immune-compromised models lacking mature FDCs reveal deficits in peripheral prion pathogenesis. 
As such a positive relationship has been firmly established between the immune-competence of the 
host and ability to support prion pathogenesis. As with most infectious agents, typical pathogenesis 
occurs via the preferred route often as a compromise between the agent and the host. Prevention or 
blocking of this route may promote adaption or alternative pathways of pathogenic activity. For 
example blocking of intestinal Peyer’s patch formation prior to oral prion infection led to pathogenesis 
via FDC contained within isolated lymphoid follicles [4]. Similar altered pathogenic routes may be 
induced following splenectomy or sympathectomy [3,20]. Data obtained from prion pathogenesis 
studies reveal that rarely infection is blocked completely and more often disease is attenuated, 
revealing alterations to well-definable characteristics such as the disease incubation period or targeting 
of pathological changes both peripherally and within the host CNS. The difficulties in analyzing such 
data are compounded by the problems of global host models (i.e., gene-knockout) that effect both 
peripheral and CNS innate or adaptive immune responses. Despite these difficulties several clear 
messages have been received regarding the role of specific components of the innate immune system, 
some of which are less inter-dependent than the systems regulating the adaptive immune response, 
which we review and summarize below. 
1.2. The Innate Immune System 
The innate immune system is considered to be a protective system that is older in evolutionary 
terms than the adaptive immune system. This system was originally proposed to respond in a  
non-specific way to invading pathogens in an attempt to eliminate them or their activity, whilst alerting 
or informing the adaptive immune response. As such the innate immune system confers no 
immunological memory or lasting protective immunity. The identification and characterization of 
specific pattern recognition receptors, such as Toll-like (TLR), C-type lectin (CLR), NOD-like (NLR) 
and RIG-I-like (RLR) receptors, has revealed the diversity of the innate immune system to detect and 
tailor specific responses to pathogen-associated molecular patterns (PAMPs) [21–24]. In line with the 
innate immune system constituting the first line of active defense after physical barrier mechanisms, a 
significant portion of the cellular component is pre-localized to potential exposure sites. This  
tissue-resident, or homeostatically maintained, population primarily assesses and responds to insults 
accordingly, and likely deals effectively with acute insults. A large systemic pool of both cellular 
(inflammatory) and proteinaceous components of the innate immune system also exists, to be 
mobilized rapidly in response to signals from epithelia or resident innate immune cells. Below we 
consider various components of the innate immune system, both cellular and proteinaceous, and their 
possible roles in prion pathogenesis (summarized in Figure 1). 
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Figure 1. Prion disease and the innate immune system. Adapted with permission from 
motifolio.com, Biomedical PowerPoint Toolkit Suite. 
 
2. Results and Discussion 
2.1. Physical Barrier to Infection: Epithelial Cells, Microfold Cells 
The epithelial cell layers constitute the first physical barrier to infection. Prion infection via the skin 
is experimentally facilitated by scarification or breaking of the keratinized epidermal barrier layers to 
allow access to the epithelial layer beneath [25]. Prion infection via the oral or nasal route appears to 
be naturally more efficient. Prion pathogenesis can be greatly enhanced by disruption of the epithelial 
layers involved in these routes [26,27]. Under steady state conditions oral uptake of prion infection 
occurs via specialized microfold cells (M-cells) localized to the follicle-associated epithelium (FAE) of 
intestinal Peyer’s patches [28,29]. The developmental maturation of M-cells has been shown to require 
CD137 signaling, with CD137 ligand provided by hematopoietic cells (either B-cells or dendritic  
cells) [30]. To provide this signal hematopoietic cells are likely required to localize to the sub-epithelial 
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vicinity via chemotaxis mediated by C-C chemokine receptor type 6 (CCR6) responding to C–C 
chemokine ligand 20 (CCL20), as M-cells do not form if CCR6-CCL20 signaling is prevented [31,32]. 
The PrPC expressed by M-cells has been hypothesized to function as an uptake receptor for pathogenic 
bacteria [33]. Translocated PrPSc has also been observed on enterocyte derived extracellular vesicles 
suggesting an M-cell independent pathway for prions to cross epithelial barriers [34]. Lumenal 
sampling by dendritic cells (DC) has been observed [35]. Although this activity by classical DC is rare 
under steady-state conditions it suggests an additional potential prion uptake mechanism. The  
de-differentiation of M-cells prior to oral scrapie infection was sufficient to block pathogenesis 
completely [29], indicating that prion uptake via epithelial and DC mechanisms are insufficient to 
establish infection in the steady state. The incidence of DC sampling increased following epithelial 
TLR signaling [36]. Thus the possibility of coincident bacterial infection or other inflammatory stimuli 
enhancing prion uptake to threshold levels via this mechanism are worthy of further investigation.  
Following uptake and translocation across the epithelial barrier layer, prions are then free to 
encounter other elements of the innate immune system. Directly beneath the FAE and within 
basolateral pockets of the M-cells themselves are areas enriched in classical DC, macrophages (Mϕ) 
and lymphocytes termed the subepithelial dome (SED), precisely located so as to process incoming 
antigen. The final physical barrier to prion pathogenesis appears to be the distance between site of 
entry and FDC and subsequently between FDC and peripheral nerves. Innervation of the lymphoid 
organs has been shown to be critical for prion neuroinvasion [20]. Manipulation to shorten the distance 
between FDC and peripheral nerves has shown to increase the rate of neuroinvasion [37]. These data 
provide a strong argument against hematogenous spread of prion agent directly to the CNS. Following 
aerosol exposure, prion pathogenesis occurs independently of the immune system, FDC, B cells,  
T cells, NK cells, lymphotoxin β receptor or CD40 ligand signaling [11]. 
2.2. Complement 
The complement system is composed of numerous blood borne proteins that are generally 
synthesized in the liver and circulate as inactive precursors or pro-proteins. Significant amounts of 
complement components are also synthesized locally by tissue-resident mononuclear phagocytes 
(MNPs) [38,39], epithelial and stromal cells such as FDC [40]. The complement system is activated by 
numerous triggers that establish a proteolytic cleavage cascade, amplifying the response and typically 
resulting in the formation of the membrane attack complex (MAC). The classical complement 
activation pathway is triggered mainly by antigen-antibody complexes. Alternative activation 
pathways exist wherein complement component C3b may bind directly to foreign material (alternative 
pathway) or where mannose-binding lectin recognizes and binds to sugar moieties (lectin pathway) 
both associated with pathogenic microorganisms. The MAC functions to form transmembrane pores, 
thereby punching holes in pathogenic cells with the aim of promoting cell lysis and death.  
Complement has been shown to be activated early during prion pathogenesis by as yet 
undetermined mechanisms and may constitute the first active response to infection. Prion protein has 
been shown to be directly bound by C1q and Factor H [41] and this binding occurs specifically when 
prion protein is conformationally modified to represent the conversion to the disease-associated 
isoform [42]. The role of complement in prion pathogenesis has recently been subject to review [43]. 
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In brief prion or TSE agents are opsonized by complement components including C1q and C3, most 
likely via the classical complement activation pathway, which may aid in their targeting of the agent to 
lymphoid follicles. Mice lacking in complement components C1qa, C2 or C3 revealed deficient 
peripheral prion pathogenesis under specific conditions [44,45].  
The local production of complement components by MNP has been shown to alter their function [46]. 
C1q enhances the receptor-mediated uptake of disease-associated PrP by classical dendritic cells (see 
section 2.4.2 below) [47]. The association of C1q with PrPSc may alter the downstream processing by 
classical DC, indeed Flores-Langarica and colleagues imply the receptor calreticulin in this process 
suggesting targeting towards a protein degradative pathway. This is counter-intuitive to the concept 
that classical DC may retain intact antigen via a FcγRIIB and complement-mediated process for 
subsequent presentation [48] which seems more likely to be a requirement for prion pathogenesis 
under the current prion hypothesis. Uptake of prion agent by other Fc receptors may mediate 
intracellular processing, e.g., for presentation on MHC class II molecules. Extreme processing of the 
prion agent is likely to render it ineffective. Cleavage of the cellular prion protein has been shown to 
protect against infection [49], whilst cleavage of PrPSc has been shown to modulate prion propagation 
in a similar fashion [50]. 
Complement component C1q also regulates dendritic cell development from monocytes via  
DC-SIGN signaling [51,52]. This induces more tolerogenic DCs and alters their cytokine production, 
leading to increased Il-10 and reduced Il-12 production and increased phagocytosis of apoptotic  
cells [53,54]. These data would suggest that C1q deficient mice may also possess a bias in their DC 
component or functions, as well as a deficiency in immune-complex trapping to FDC, further 
complicating the interpretation of prion pathogenesis studies performed within them.  
The role of complement during prion pathogenesis is further complicated by the observation that 
the individual complement components mediating interaction with PrPSc appear to differ dependent 
upon the strain of infectious agent [55]. Cell-autonomous and complement-assisted cell-mediated 
waves of prion trafficking occurs to lymphoid follicles, the relevance of each transport mechanism to 
disease pathogenesis remains undetermined [56]. 
The role of the complement system within the CNS has also been extensively reviewed recently [57,58]. 
As with most innate immune functions within the CNS a clear neuroprotective/neurodegenerative 
dichotomy exists within the literature, likely indicative that complement activation may lead to both 
protective and degenerative effects dependent upon the context, responsive and regulatory mechanisms 
involved. There is currently little evidence supporting a role for complement in prion pathogenesis 
within the CNS. Mice lacking C1qa, C2 or C3 revealed no deficit to prion pathogenesis following 
intracerebral inoculation [44] and mice lacking both complement components C3 and C4 revealed 
unaltered pathogenesis following aerosol exposure to prions [11]. 
2.3. Mast Cells 
Mast cells have been implicated in prion pathogenesis due to their high expression levels of cellular 
prion protein (PrP or PrPC) and their ability to traffic to the brain [59]. In fact mast cells are resident, 
and are also capable of trafficking from the blood to specific regions within the CNS. These different 
populations of mast cells differentially express the c-kit receptor [60]. Mast cells function to release 
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histamine (via binding of allergens to FcεR1α) and heparin in an early response to infection, and are 
critical to induce chemotaxis and infiltration of neutrophils and MNPs. Due to the non-inflammatory 
nature of prion infection there is little evidence to suggest that mast cells undertake this conventional 
role during peripheral prion pathogenesis. Studies of the activation pathways in mast cells reveal that 
other factors such as C3a and CCL3 may trigger mast cell degranulation without IgE binding to 
FcεR1α [61]. This activation pathway is most likely to occur during prion pathogenesis as there is little 
evidence of the induction of an adaptive immune response and specific anti-prion antibody generation 
during pathogenesis. The role of immediate local responses to prion infection is in clear need of further 
investigation to determine the activation effects on mast cells, MNPs and neutrophils amongst other 
innate immune cell types. 
The role of mast cells within the brain is thought to be neuro-modulatory and mast cell trafficking 
to the brain is linked to steroidal hormones and sexual activity or anxiety behaviors [62]. The presence 
of mast cells within the brain and their ability to shed expressed PrP upon activation [59] may have 
implications for prion pathogenesis within the CNS. Shedding of PrPC by mast cells likely occurs via 
proteolytic or lipolytic cleavage mechanisms removing the glycosylphosphatidylinisotol (GPI) anchor 
from the protein [59,63]. Activation of mast cells within the CNS may provide copious extracellular 
PrPC substrate for conversion to the disease-associated isoform late in the disease process, when 
significant damage has occurred to the CNS already, adding to the exponential accumulation of 
misfolded protein within the clinical stage of disease. Investigation of GPI-anchorless PrP transgenic 
mice has revealed that they are capable of forming amyloid in the brain without clinical prion disease 
symptoms, whilst co-expression of anchorless and native PrPC increased prion pathogenesis [64]. 
Novel synthetic prion strains have subsequently been generated in the above mentioned co-expressing 
model [65], suggesting that mast cell involvement during infection may aid in or promote the natural 
prion strain mutation [66] or prion evolution phenomena [67]. 
2.4. Mononuclear Phagocytes: Microglia, Macrophages, Monocytes, Dendritic Cells and  
Langerhans Cells 
MNP constitute a system of highly phagocytic cells that have a common origin in the bone marrow 
and circulate or reside in the body tissues in order to sample their environment via uptake of foreign 
(and self) material. The development of MNP relies upon expression of the colony stimulating factor 1 
receptor (CSF-1R) during their differentiation in order to respond to CSF-1. MNP play a vital role in 
the bridge between the innate and adaptive immune systems by processing and presenting of antigenic 
compounds to stimulate specific antibody production. During the initial processing by MNP material 
may be directly disposed of by degradation via lysosomal or proteasomal pathways. These actions of 
MNP aid in the development of immunity or tolerance to the vast multitude of foreign material 
encountered. Numerous (particularly intracellular) pathogens have adapted to abuse the functions of 
MNP as a vehicle for pathogenesis, allowing for their uptake into MNP and trafficking to lymphoid 
organs for further spread. It is most likely that the uptake and spread of prions to lymphoid organs 
occurs using MNP as a ‘Trojan horse’ via a similar mechanism. 
The role of MNP in prion pathogenesis have been subject to recent review and are considered 
diverse [68]. This reflects the wide diversity of MNP and their roles in innate immunity. To simplify 
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this diversity MNP can be broadly categorized into the following: (1), resident cells with degradative 
functions; (2) resident cells with antigen presenting functions and (3) systemic circulating cells responsive 
to inflammatory stimuli. At present there is little evidence implicating circulating ‘inflammatory 
monocyte’ populations in prion pathogenesis due to the non-inflammatory nature of infection.  
Regardless of their major functionality all MNP likely use similar surface receptor based pathways 
and mechanisms to sense their local micro-environment and tailor their responses to pathogens or 
tissue damage. The exact receptor-mediated mechanism determining the response to prion agents has 
not been identified or definitively characterized. MNP-mediated uptake of prion agent is enhanced by 
complement opsonization (see Section 2.1 above). The uptake of prions likely involves complement, 
lectin or scavenger receptors while there is evidence that Fc [44] (FcγR, RII and RIII deficient mice 
reveal no deficit following i.c. or i.p. inoculation), or toll-like receptors [69] (at least via the Myd88-
dependent pathway) have little role in peripheral pathogenesis under steady state conditions. The 
downstream processing of the prion agent will likely depend upon the MNP type it has been 
encountered by. 
2.4.1. Degradative MNP  
The expression of cellular prion protein in MNP has been associated with phagocytic ability and 
modulation of inflammatory responses [70–72]. Evidence suggests that macrophages (generally 
identifiable by the markers integrin alpha M, Macrosialin or the F4/80 antigen) degrade the prion  
agent [73]. The degradative and prion clearance abilities of macrophages appear to be down-regulated 
when macrophage (Mϕ) activation is stimulated by other danger signal molecules [74]. Again the 
mechanism of degradation is unknown but represents a critical therapeutic target as it constitutes a 
natural regulatory mechanism to prion pathogenesis. Stimulating or enhancing this degradative ability 
may improve peripheral resistance to prion infection. The degradation of agent is countered by the 
relative replicative ability of the prion agent and its spread through the host. While much has been 
postulated regarding the prion protein sequence, protein folded conformation and glycosylation in 
constituting the relative ‘species-barrier’ effect observed relating to limited or lack of cross-species 
infection ability of specific strains of prion agent (for review see [75]). An alternate hypothesis is to 
suggest that in prion infection with low or poor replicative ability (i.e., due to the factors mentioned 
above) the balance is switched in favor of degradation of agent, thereby preventing or dramatically 
slowing pathogenesis. This may occur both within any given cell (and not exclusively to degradative 
or phagocytic cell types), in fact it is well known that there are limited in vitro cell infection models in 
the prion field due to the relevant inability to infect numerous cell types with a variety of prion strains 
even within the same species [76], and within the complexity of the host innate immune response. 
Cellular degradation of PrPSc has been shown to be inhibited by cysteine protease inhibitors [77].  
It has also been shown that prions may be taken up and trafficked to the endosomal compartment [78] 
one possible intracellular site of PrPC to PrPSc conversion [79]. The role of Rab GTPase proteins and 
their effectors shifting the balance of trafficking away from recycling endosomes and towards late 
endosomal/lysosomal pathways may play a pivotal role in the cellular decision between propagation 
and degradation of prions [79]. The cellular ability to uptake and degrade prions appears to be 
independent of cellular prion protein expression [80,81].  
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2.4.2. Antigen Presenting Cells (APC) 
APC have long been identified as being critical to prion pathogenesis. While evidence exists for 
both cell-free and cell-mediated transport of prions to lymphoid tissues [56], removal of the  
cell-mediated trafficking severely hampers prion pathogenesis. The basis of cell-mediated trafficking 
lies in chemotactic efflux of APC to lymph nodes during their maturation [5,82]. The initial phase of 
transport results from the linked down-regulation of CCR6 and up-regulation of CCR7 allowing APCs 
to relocate to lymphoid follicles [83]. Prion infection of ‘plt’ mice (deficient in CCL19/CCL21) 
revealed delayed pathogenesis following transcutaneous infection attributable to impaired CCR7-mediated 
chemotaxis of DC [82]. Following oral prion infection altered homeostasis in DC levels has been 
reported in intestinal Peyer’s patches [84]. Transient depletion of CD11c-expressing cells (a commonly 
used marker indicative of classical DC) revealed the ability to completely block or severely impair 
pathogenesis via oral and intraperitoneal routes [85,86]. This depletion strategy was observed to 
eliminate all MNP types from the intestine, including classical DC and macrophages, suggesting that 
neither transport nor degradation are actively occurring during depletion [87]. Depletion models of 
CD11c+ CD8+ (in this case CD8αα) DC subsets restricts intraperitoneal but not oral pathogenesis 
suggesting that alternative DC subsets may be employed following different infection routes. CD8 
knockout mice revealed no alteration of prion pathogenesis, suggesting no direct role for CD8 [88]. 
This paradigm seems more clearly established in the parenteral ‘skin scarification’ model route of 
infection. In this model numerous DC and Langerhans cell (LC, expressing the marker Langerin) MNP 
types are known to interact with the prion agent but the depletion of non-epidermal CD11c+ cells had 
the biggest impact upon pathogenesis [89]. Extracted cell populations representing classical DC and 
plasmacytoid DC (pDC) have been shown to be capable of transfer of infection in vivo [90] and  
in vitro [91] respectively. These findings strongly link these cell types to the retention of intact prion 
agent and, in the case of classical DC, traffic of the agent in the pre-neuroinvasive stage of prion 
infection. Resident macrophage cell types within lymphoid organs have so far been shown to have 
little impact upon disease pathogenesis, indicating that cell free material arriving at the lymphoid  
tissue is either sequestered to FDC (via complement opsonization) or degraded by resident tingible body 
macrophages. 
2.4.3. MNP in the CNS 
Within the CNS the innate immune response is mediated by specialized MNP known as microglia. 
Microglial development is also dependent upon signaling via the CSF1-R [92], however microglial 
population of the CNS appears to require both CSF-1R ligands; interleukin-34 (Il-34) [93] and CSF-1 [94]. 
Microglia activated by amyloidogenic peptides including PrP106-126, also reveal enhanced survival and 
proliferative responses to CSF-1 [95]. Following peripheral prion infection the microglia show signs of 
activation after neurons and astrocytes have responded. These findings suggest that microglia do not 
respond directly to presence of misfolded prion protein per se but may require priming by other CNS 
cell types. Following priming the microglial cells undergo chemotaxis to the site of insult [96], 
impairment of this chemotaxis by knockout of CXCR3 revealed altered central prion pathogenesis [97]. 
Once activated the microglial population expands and has been shown to upregulate various markers 
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including Trem2, SiglecF, CD200R, and Fcγ receptors in a non-classical immune-response [98].  
In fact many of the CNS gene expression profiling studies focused on prion infected CNS have 
repeatedly identified genes strongly associated with MNP activation (Table 1). Together these data 
suggest that MNPs constitute the most clinically relevant target innate immune cell population both 
within and without the CNS during prion pathogenesis.  
Table 1. Many of the following genes/proteins have been proven or implicated to have a 
role in the interaction between prion pathogenesis and the innate immune system and are 
mentioned in this review. 
Gene name Gene Uniprot Phase a Ref 
Allograft inflammatory factor 1 Aif1 / Iba1 O70200 M [99] 
B-cell differentiation antigen CD72 Cd72 / Ly32, Lyb-2 P21855 M [98] 
Beta-2-microglobulin B2m P01887 M [99,100] 
Calreticulin Calr / CRP55 P14211 E [47] 
C3a anaphylatoxin chemotactic receptor C3ar1 O09047 M [101] 
CAMPATH-1 antigen Cd52 / Mb7 Q64389 E [99,100,102] 
C–C chemokine receptor type 5 
Ccr5 / MIP-1αR, 
CD195 
P51682 E [96,103] 
C–C chemokine receptor type 6 Ccr6 / CD196 O54689 E [104] 
C–C chemokine receptor type 7 
Ccr7 / MIP-3βR, 
CD197 
P47774 E [82] 
C–C motif chemokine 2 Ccl2 / MCP-1 P10148 E [105–107] 
C–C motif chemokine 3 Ccl3 / MIP-1α P10855 E [100,105,106] 
C–C motif chemokine 4 Ccl4 / MIP-1β P14097 E [106] 
C–C motif chemokine 5 Ccl5 / RANTES P30882 M [105] 
C–C motif chemokine 7 Ccl7 / MCP-3 Q03366 M [103] 
C–C motif chemokine 9 Ccl9 / MRP-2 P51670 M [99,102] 
C–C motif chemokine 12 Ccl12 / MCP-5 Q62401 M [99,102] 
C–C motif chemokine 19 Ccl19 / ELC O70460 E [82] 
C–C motif chemokine 20 
Ccl20 / MIP-3α, 
Exodus-1 
O89093 E [104] 
C–C motif chemokine 21a 
C–C motif chemokine 21b 
C–C motif chemokine 21c 
Ccl21 / Exodus-2 
P84444 
P86792 
P86793 
E [82] 
CD9 antigen Cd9 P40240 M [99,108] 
CD40 ligand 
Cd40lg / Gp39, 
CD154 
P27548 E [109–111] 
CD48 antigen Cd48 / BLAST-1 P18181 E [106] 
CD209 antigen-like protein A b Cd209a / DC-SIGN Q91ZX1   
Cell surface glycoprotein CD200 receptor 4 Cd200r4 Q6XJV4 M [98] 
CMRF35-like molecule 8 Cd300a / MAIR1 Q6SJQ0 M [98] 
Complement C1q subcomponent subunit A 
Complement C1q subcomponent subunit B 
Complement C1q subcomponent subunit C 
C1qa 
C1qb 
C1qc 
P98086 
P14106 
Q02105 
E 
E 
E 
[41,44,45,47, 
100,101,106] 
Complement C2 C2 P21180 E [44] 
Complement C3 C3 / HSE-MSF P01027 M [44,45,100,101] 
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Table 1. Cont. 
Gene name Gene Uniprot Phase a Ref 
Complement C4-B C4B P01029 E [41,99,101,102] 
Complement C5 C5 P06684  [112] 
Complement C7 c C7 D3YXF5 E [113] 
Complement component C1q receptor Cd93 / C1qRp, Ly68 O89103   
Complement receptor type 1 CR1 / CD35 P17927 E [44,114] 
Complement receptor type 2 CR2 / CD21 P19070 E [44,114–116] 
C-type lectin domain family 4 member K Cd207 / Langerin Q8VBX4   
C-type lectin domain family 7 member A Clec7a / Dectin1 Q6QLQ4 E [99,101,102] 
C-type lectin domain family 11 member A Clec11a / Scgf O88200 L [108] 
CX3C chemokine receptor 1 Cx3cr1 Q9Z0D9 E [106,117] 
C-X-C motif chemokine 9 Cxcl9 / MIG, Scyb9 P18340 M [118] 
C-X-C motif chemokine 10 
Cxcl10 / Crg2, Ifi10, 
Inp10, Scyb10 
P17515 E 
[100,105, 
109,113] 
C-X-C motif chemokine 11 
Cxcl11 / I-TAC, 
Scyb11 
Q9JHH5   
C-X-C motif chemokine 13 Cxcl13 / BLC, Scyb13 O55038 E [109] 
C-X-C chemokine receptor type 3 
Cxcr3 / Cmkar3, 
CD183 
O88410 M [97] 
C-X-C chemokine receptor type 4 
Cxcr4 / Cmkar4, Lestr, 
Sdf1r, CD184 
P70658 M [103] 
C-X-C chemokine receptor type 5 
Cxcr5 / Blr1, Gpcr6, 
CD185 
Q04683 L [109] 
EGF-like module-containing mucin-like 
hormone receptor-like 1 
Emr1 / GpF4/80 Q61549 E [119] 
Eotaxin Ccl11 / Syca11 P48298   
Forkhead box protein P3 Foxp3 Q99JB6  [120] 
Formyl peptide receptor-related sequence 1 
Fpr-s1 / Fpr2, Fpr3, 
Fprl1, Lxa4r 
O08790  [121] 
Galectin-3 Lgals3 / MAC-2 P16110 E [106] 
Galectin-3-binding protein 
Lgals3bp / Cycap, 
Mama 
Q07797 E [99,101] 
Granulins Grn / PCDGF  P28798 E [99,117,122] 
Granulocyte-macrophage colony-
stimulating factor 
Csf2 / GM-CSF P01587 M [105] 
Granzyme B Gzmb / Ctla1 P04187   
Growth-regulated alpha protein 
Cxcl1 / Gro, Gro1, 
Mgsa, Scyb1 
P12850 E [105] 
Guanylate-binding protein 4 Gbp4 / Gbp3 Q61107 M [99] 
H-2 class I histocompatibility antigen,  
D-37 alpha chain 
H2-T23 P06339 M [99] 
H-2 class I histocompatibility antigen,  
D-D alpha chain 
H2-D1 P01900 M [99] 
H-2 class I histocompatibility antigen,  
K-B alpha chain, 
H2-K1 Q7TN03 E [99] 
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Table 1. Cont. 
Gene name Gene Uniprot Phase a Ref 
Hematopoietic progenitor cell antigen 
CD34 
Cd34 Q64314  [123] 
High affinity immunoglobulin epsilon 
receptor subunit alpha 
Fcer1a / FcεR1α P20489   
High affinity immunoglobulin epsilon 
receptor subunit gamma 
Fcer1g / FcεR1γ P20491 M 
[99,101,102, 
117,122] 
High affinity immunoglobulin gamma Fc 
receptor I 
Fcgr1 / FcγRI, CD64 P26151 E [44,98] 
IgG receptor FcRn large subunit p51 Fcgrt / FcRn Q61559 E [124] 
Integrin alpha-4 Itga4 / CD49d Q00651 E [125] 
Integrin alpha-X Itgax / CD11c Q9QXH4 E 
[9,85,90,100, 
115,126] 
Integrin alpha-M Itgam / CD11b P05555 E [96,100,127] 
Integrin beta-1 Itgb1 / VLA-4β, CD29 P09055  [128] 
Integrin beta-2 Itgb2 / CD18 P11835 E [101,117] 
Integrin beta-7 Itgb7 P26011  [125] 
Interferon alpha-inducible protein 27-like 
protein 2A 
Ifi27 Q8R412 E [99] 
Interferon-induced protein with 
tetratricopeptide repeats 1 
Ifit1 Q64282 M [99] 
Interferon-induced protein with 
tetratricopeptide repeats 3 
Ifit3 Q64345 L [99,108,122] 
Interferon-induced transmembrane 
protein 3 
Ifitm3 Q9CQW9 E [99,108] 
Interferon gamma Ifng / IFNγ P01580 M [105,129] 
Interferon gamma receptor 1 
Ifngr1 / IFNγR1, 
CD119 
P15261   
Interleukin-1 alpha Il1a / Il1α P01582 E 
[105,106, 
108,117] 
Interleukin-1 beta Il1b / Il1β P10749 E 
[105,117, 
118,129] 
Interleukin-1 receptor type 1 Il1ra / IL1Rα, CD121a P13504 M [118,130] 
Interleukin-2 Il2 P04351 E  
Interleukin-2 receptor subunit alpha Il2ra / Il2Rα, CD25 P01590 E [120] 
Interleukin-4 Il4 P07750 E [131] 
Interleukin-6 Il6 P08505 M [105,129,132] 
Interleukin-10 Il10 P18893 E [130,131] 
Interleukin-12 subunit alpha 
Interleukin-12 subunit beta 
Il12p35 
IL12p40 
P43431 
P43432 
 
E 
[105,133] 
Interleukin 13 Il13 P20109 M [105,131] 
Interleukin 15 Il15 P48346   
Interleukin 18 Il18 P70380   
Interleukin 34 Il34 Q8R1R4   
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Table 1. Cont. 
Gene name Gene Uniprot Phase a Ref 
Killer cell lectin-like receptor subfamily 
B member 1 
Klrb1 / NK1.1, CD161 Q0ZUP1   
Leukocyte-associated immunoglobulin-
like receptor 1 
Lair1 / CD305 Q8BG84 L [98] 
Leukocyte surface antigen CD47 Cd47 / IAP Q61735 L [108] 
Leukocyte surface antigen CD53 Cd53 Q61451 M [99,100] 
Low affinity immunoglobulin gamma Fc 
region receptor II 
Fcgr2b / FcγRIIB, 
CD32 
P08101 M 
[44,98,99,101, 
102,117] 
Low affinity immunoglobulin gamma Fc 
region receptor III 
Fcgr3 / FcγRIII, CD16 P08508 M 
[44,98,99,101, 
102,117] 
L-selectin 
Sell / Ly22, LAM1, 
LECAM1, CD62L 
P18337 E [106] 
Lymphocyte antigen 6C1 Ly6c1 / Ly-6C P0CW02 M [108,122] 
Lymphocyte antigen 75 
Ly75 / DEC-205, 
CD205 
Q60767 E [127,134] 
Lymphocyte antigen 86 Ly86 / Md1 O88188 E 
[99,102,106, 
108,122,135] 
Lymphotoxin-alpha 
Lta / LTα, TNFβ, 
Tnfsf1 
P09225 E [125,136] 
Lymphotoxin-beta 
Ltb / LTβ, Tnfc, 
Tnfsf3 
P41155 E [136] 
Lysozyme C-2 Lyz2 / Lyzs P08905 M [99,102,137] 
Macrophage colony-stimulating factor 1 Csf1 / MCSF P07141 M  
Macrophage colony-stimulating factor 1 
receptor 
Csf1r / c-fms, CD115 P09581 M [117] 
Macrophage receptor MARCO Marco Q60754 E [138] 
Macrophage scavenger receptor types I 
and II 
Msr1 / Scvr, SRA, 
CD204 
P30204 E [138] 
Macrosialin Cd68 P31996 E 
[99,100,101, 
106,115,127] 
Mannose-binding protein A 
Mannose-binding protein C 
Mbl1 / MBP-A 
Mbl2 / MBP-C 
P39039 
P41317 
  
Mast cell surface glycoprotein Gp49A Gp49a Q61450 M [98] 
Mast/stem cell growth factor receptor Kit 
Kit / SCFR, c-Kit, 
CD117 
P05532   
MicroRNA 146a miR-146a  E [139] 
Monocyte differentiation antigen CD14 Cd14 P10810 E [101,106,115] 
Myeloid cell surface antigen CD33 Cd33 / Siglec3 Q63994 M [98] 
Myeloid differentiation primary response 
protein MyD88 
Myd88 P22366  [69] 
Perforin Prf1 / Pfp P10820   
Probable C–C chemokine receptor type 3 
Ccr3/ Cmkbr1l2, 
Cmkbr3, MIP-1αRl2, 
CD193 
P51678 M [103] 
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Table 1. Cont. 
Gene name Gene Uniprot Phase a Ref 
Prion protein Prnp / PrP, CD230 P04925 E [140,141] 
Receptor-transporting protein 4 Rtp4 / Ifrg28 Q9ER80 E [99] 
Scavenger receptor cysteine-rich type 1 
protein M130 
Cd163 / M130 Q2VLH6 E [113] 
Sialic acid-binding Ig-like lectin 5 
Siglec5 / SiglecF, 
CD170 
Q920G3 M [98] 
Sialoadhesin 
Siglec1 / Sa, Sn, 
CD169 
Q62230 E [142] 
SLAM family member 5 Cd84 / Slamf5 Q18PI6 L [101] 
Sphingosine 1-phosphate receptor 1 S1pr1 / Edg1, CD363 O08530 E [143] 
Stromal cell-derived factor 1 Cxcl12 / SDF-1 P40224 E [113] 
T-cell surface glycoprotein CD3 gamma 
chain 
Cd3g / TCRγ P11942 M [116] 
T-cell surface glycoprotein CD3 delta 
chain 
Cd3d / TCRδ P04235 M [116] 
T-cell surface glycoprotein CD4 Cd4 P06332 M [116,120,144] 
T-cell surface glycoprotein CD8 alpha 
chain 
Cd8a / CD8α P01731 E [9,116,144,145] 
TGF-beta receptor type-2 Tgfbr2 / TGFβR2 Q62312 M [130] 
TNF receptor-associated factor 5 Traf5 P70191 L [108] 
Toll-like receptor 2 Tlr2 / CD282 Q9QUN7 M [101] 
Transforming growth factor beta-1 Tgfb1 / TGFβ1 P04202 M 
[108,130, 
146,147] 
Triggering receptor expressed on myeloid 
cells 2 
Trem2 Q99NH8 M [98,99] 
Tumor necrosis factor Tnfa / TNFα P06804 E 
[106,108, 
130–132] 
Tumor necrosis factor ligand superfamily 
member 9 
Tnfsf9 / Cd137l, 
Cd157l, Ly63l  
P41274 E  
Tumor necrosis factor receptor 
superfamily member 1A 
Tnfr1 / CD120a P25118 E [130,148,149] 
Tumor necrosis factor receptor 
superfamily member 1B 
Tnfr2 / CD120b P25119 E [130] 
Tumor necrosis factor receptor 
superfamily member 9 
Tnfrsf9 / Ly63, CD137 P20334 E  
Tumor necrosis factor ligand superfamily 
member 11 
Tnfsf11 / RANKL, 
CD254 
O35235 E [29] 
TYRO protein tyrosine kinase-binding 
protein 
Tyrobp / DAP12, 
CD300d 
O54885 E [98,99,101] 
Tyrosine-protein phosphatase non-
receptor type substrate 1 
Sirpa / Sirpα1, 
CD172a 
P97797 E [115] 
a Reported involvement phase of genes during prion pathogenesis, occurring (E)arly <50%; (M)id 50%–90% 
or (L)ate >90% during disease incubation period. Data also extrapolated from [150]; b There are 5 murine 
homologues (A–E) of human DC-SIGN; c From MGI:88235 unreviewed Uniprot entry. 
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2.5. Granulocytes: Neutrophils, Basophils and Eosinophils 
Gene expression data reveal that PrP expression is generally down-regulated during granulocyte 
differentiation [151] though some expression is still detectable [152] (see also Figure 2). Neutrophil 
functions have been shown to be inhibited by both native and scrapie associated prion protein, 
resulting in failure of neutrophil aggregation and deficits in superoxide radical and beta-glucuronidase 
export [153]. A 20 amino acid fragment of the prion protein sequence (termed PrP106-126) has been 
shown to be directly neurotoxic, activate MNPs and act as a chemotactic agonist for the FPRL1 
receptor [121]; the relevance of the PrP106-126 fragment to prion pathogenesis is elusive at best. FPRL1 
is strongly expressed on granulocytes and MNP cell types and promotes chemotaxis to sites in 
response to allergic inflammation [154]. Eosinophilic inclusions have been observed in both central 
and peripheral amyloid deposits, although amyloid deposits themselves are eosinophilic, there is some 
evidence to suggest eosiniophils are present within or around peripheral amyloid deposits. The basis 
for this localization appears to lie in FPRL1 chemotaxis. 
2.6. Natural Killer Cells and γδ T Cells 
Natural killer (NK) and γδ T cells are thought to play little role in the pathogenesis of prion 
diseases. Both cell types require triggering or activation by danger signals, for NK cell this is usually 
via cytokines and for γδ T cells little is known about their activating signals. NK cells primarily 
respond to virally-infected cells and function to destroy these cells via expression of perforin and 
granzyme. Perforin-knockout mice revealed unaltered prion pathogenesis [88]. NK cells are typically 
stimulated via interleukins, 2, 12, 15 and 18 and chemokine CCL5 as well as down-regulation of MHC 
class I molecules following viral infection. The lack of reported NK cell response to prion 
pathogenesis suggests that prion agent uptake by monocytes may fail to activate NK cells. There are 
numerous viral mechanisms used to evade NK cell activation including regulating apoptosis, 
modulating cytokines and chemokines, and compromising DC functions for review see [155–157]. 
Little evidence has been discovered for any of these functions following prion infection apart from the 
possible induction of apoptotic cell death mechanisms (in neurons). Recently NK/T cells (a subset of 
T-cells that express both the NK1.1 marker and αβ T cell receptor) in the spleen have been associated 
with prion infectivity [91]. Investigating the role of NK/T cells in prion pathogenesis is hampered by 
the fact that though Rag2−/− mice are deficient in NK/T cells they are unsusceptible to prion infection 
due to their B-cell deficiency and failure to generate mature FDC. Selective reconstitution of the 
Rag2−/− model for prion pathogenesis studies has not been reported. An increase in γδ T cells in the 
peripheral blood mononuclear cells (PBMCs) has been reported following scrapie infection in sheep [116]. 
2.7. Megakaryocytes and Platelets 
The megakaryocyte lineage and platelets have been associated with the expression of prion  
protein [123,158] and MicroRNA miR146a [159]. Following activation of platelets PrPC is released in 
exosomes [160], similar to the release of exosomal PrPC from macrophages [161]. While not 
classically considered part of the innate immune system, evidence regarding the expression of TLR2 
having a regulatory function has suggested a new role for megakaryocytes in immunity [162]. The 
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over-expression of miR146a, TLR2 and TLR4 has also been reported in microglial cells during scrapie 
(prion) infection [139]. These data may indicate some common co-expression mechanism of these 
genes or their possible functional interaction. Regardless of their role in immunity megakaryocytes and 
platelets constitute a significant portion of the PrP expressing bodies within the blood compartment 
and as such represent a major vector for prion transmission during blood transfusion [163–166]. 
Spread of prion infection between lymphoid organs (i.e., from draining to contralateral non-draining 
lymph nodes) has been prevented by blocking the egress and thus recirculation of B-cells [143]. The 
routing of prion pathogenesis has been characterized in precise immunohistological detail and 
describes neuroinvasion from lymphoid organs via the peripheral nervous system [167,168]. 
Hematogenous spread from lymphoid organs to the CNS has been proposed as an alternative or 
complementary pathway to neuroinvasion in natural ruminant prion disease with involvement of the 
circumventricular organs (CVO) in the CNS [169].  
2.8. Prion Protein Expression 
Expression of the cellular prion protein (PrPC) by the hematopoietic compartment is not required for 
prion pathogenesis [170], confirming that the innate immune system function in disease pathogenesis 
operates via non-PrPC dependent mechanisms. Little is known about the uptake mechanisms of prions 
and the factors that lead to cell clearance, infection or passivity that may facilitate transport. PrPC is not 
required for uptake of prions in vitro, even by non-phagocytic cell types such as neurons [171]. There 
has been much debate regarding which cells of the immune system do or do not express appreciable 
levels of PrP. It has long been known that PrP is strongly expressed on hematopoietic stem cells within 
the bone-marrow compartment; specific lineages appear to lose or down-regulate this expression 
during differentiation [172,173]. Maturation of cells in response to all-trans retinoic acid is one 
mechanism known to down-regulate PrP expression [151]. In light of the current debate regarding 
hematopoietic differentiation and retention or loss of PrPC expression we present here data on the 
expression of the prion protein gene (Prnp) transcripts in various innate immunity relevant cellular 
compartments (Figure 2). The ability to detect Prnp gene expression and cellular prion protein differ, 
indeed it appears that the mature protein is often more labile or difficult to detect than its 
corresponding mRNA message, possibly accounting for some of the reported discrepancies [174,175]. 
The data we present here clearly depicts altered Prnp expression levels between subcomponents of the 
hematopoietic system with Mϕ, DC, Microglia, LC and IFN-producing killer DC displaying the 
highest observable levels of expressed Prnp transcript.  
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Figure 2. (a) Prnp expression profiling using Affymetrix GeneChip Mouse Genome 430 
2.0 Array probesets 1416130_at and (b) 1448233_at; data from [176]. BM, bone marrow; 
HSC, hematopoietic stem cells; CMP, common myeloid progenitor; GMP, granulocyte-
macrophage progenitor; CLP, common lymphoid progenitor; BMDM, bone marrow-derived 
macrophage; LC, Langerhans cell; BMDC, bone marrow-derived dendritic cell; DC, 
dendritic cell; pDC, plasmacytoid dendritic cell; IKDC, interferon-producing killer 
dendritic cell; NK, natural killer. 
 
2.9. Transgenic Mice Models 
The most common mechanism for determining or proving a correlation between components of the 
innate immune system (be they cells or proteins) and prion pathogenesis is via transgenic mouse 
models. These models have been used to determine the effect of knockout or overexpression of a 
particular protein or cell type on prion pathogenesis. The classic experiment revealed that knockout of 
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Prnp resulted in complete resistance to prion infection [140,141]. A plethora of immunity-associated 
candidate genes have been identified by observational techniques e.g., following gene expression 
profiling and numerous genes have been screened for a role in prion pathogenesis via knockout 
transgenic mouse models, e.g., [130] (see also Table 1). The majority of such studies have determined 
that knockout of an individual component does not prevent prion pathogenesis, for some a slight 
alteration in pathogenesis was observed and for relatively few a block of pathogenesis was observed 
and then often only under certain specific conditions. We have performed a pathway analysis of the 
innate immunity associated genes implicated in prion pathogenesis and determined the major host 
upstream regulators of prion pathogenesis-associated gene expression (Table 2).  
Table 2. Major upstream regulators of genes implicated in prion pathogenesis (Table 1), as 
determined by Ingenuity pathway analysis IPA (Ingenuity® Systems, www.ingenuity.com). 
Upstream regulator Acronym P-value of overlap # of genes 
Interleukin-4 Il-4 5.85E-68 73 
Interleukin-12 IL-12 4.89E-64 49 
Interferon gamma IFNγ 1.32E-63 80 
Interleukin-10 IL-10 3.85E-63 56 
Interleukin-2 IL-2 1.05E-56 58 
Tumor necrosis factor TNF 2.70E-53 80 
Interleukin-6 IL-6 9.31E-49 57 
Colony stimulating factor 2 CSF2 2.85E-46 43 
From these candidates all have previously been implicated with prion pathogenesis, Il-4, Il-6 and  
Il-12 have been shown not to be required. Il-10 knockout mice revealed major alterations to, but not 
prevention of, prion pathogenesis. These data reveal the cytokine milieu occurring during prion 
pathogenesis and may underlie the basis of alternative activation of MNP and lack of inflammatory, or 
tolerization of, responses during prion infection. These upstream regulators accounted for 118 out of 
the 144 genes analyzed presented as a wheel network diagram to reveal the overlap between the 
regulators and target genes (Figure 3), perhaps revealing why knockout of any individual component 
may have little overall effect upon prion pathogenesis. Many of these genes and their regulators effect 
MNP differentiation, maturation and homeostasis as well as modulating MNP responses during 
infection. These findings indicate that prion pathogenesis is influenced by the steady-state, activation 
and response of the innate immune system. 
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Figure 3. Wheel network diagram showing the overlap of the major upstream regulators of 
genes implicated in prion pathogenesis. The network was generated through the use of IPA 
(Ingenuity® Systems, www.ingenuity.com).  
 
3. Summary and Conclusions  
In summary the innate immune system has many and varied roles in the response to prion pathogenesis, 
providing both the means to facilitate spread of infection and natural mechanisms to combat infection. 
The activation (or alternative activation) of mononuclear phagocyte cells appears critical to both 
peripheral and central prion pathogenesis through as yet unidentified receptors and signaling pathways. 
Investigation of the expression and function or cellular prion protein has clearly identified widespread 
expression throughout cell types of the innate immune system and has also suggested possible 
immune-system specific functions of PrP separate from its possible roles within the CNS. 
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